advertisement
Abstract #16002 Published in IGR 2-3
A comparison between latanoprost and timolol in treatment of patients with primary open-angle glaucoma and ocular hypertension
Peng D; Li S; Li MChinese Journal of Ophthalmology 2000; 36: 285
OBJECTIVE: To evaluate the therapeutic value of latanoprost on glaucoma. METHODS: In an open-label fashion, multicenter, randomized control clinical trial, the efficacy and adverse drug reactions of the topical application of 0.005% latanoprost once daily were compared with that of 0.5% timolol twice daily for 12 weeks in patients with open-angle glaucoma or ocular hypertension. RESULTS: The study initially included 128 patients (63 in the latanoprost group, and 65 in the timolol group), with 117 still remaining at the end of the study (60 in the latanoprost group and 57 in the timolol group). Comparing 12 weeks with baseline diurnal intraocular pressure (IOP), the reduction of IOP (mean ± SD) in the latanoprost group was 7.5 ± 0.3 mmHg (1 mmHg = 0.133 kPa) (32%, t = 22.73, p < 0.0001) greater than the reduction in the timolol group (6.1 ± mmHg, 26%, t = 17.94, p < 0.0001), the difference between the two groups being significant (f = 9.54, p = -00026). Two patients treated with timolol and none treated with latanoprost were withdrawn from the study because of inadequate IOP control; three patients with latanoprost had foreign body sensation. In the latanoprost group, there was one patient whose eyelashes had become darker and longer at the last visit (the 12th week). No ocular or systemic adverse events related to either drug were found. CONCLUSIONS: It has been demonstrated that 0.005% latanoprost topically applied once daily is well tolerated and is more effective in reducing IOP than 0.5% timolol topically applied twice daily. Thus, latanoprost has the potential to be a new first-line antiglaucoma drug.LA: Chinese
Dr. D. Peng, Zhongshan Ophthalmic Center, Sun Yat-sen University of Medical Sciences, Guangzhou 510060 China
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
